Psychedelics News April 2020

Psilocybin has been made in yeast in the lab, which could mean even easier (and more accessible) production and distribution of it in the future. A lot of companies keep expanding and MindMed takes the headline a few times. A lot of the research is taking a pause, as COVID-19 ravages through the world.

Psychedelics Research Recap March 2020

New evidence piles up for the use of psychedelics in the fight against depression. Classical psychedelics seem to be longer-lasting in their effect than ketamine. And people can be fooled into thinking they are tripping, by carefully manipulating the setting.

How Big is the Truffles Industry in The Netherlands – Worldwide Predictions

Today we’re exploring the size of the truffles industry in The Netherland. It’s an exploration that will take a look at the (web)shops, use prevalence, and the expected market size. Although it’s very difficult to find exact numbers about revenue, this blog should be a starting point and a rough estimate. In the end, there will also be an extrapolation to guestimate worldwide usage and revenue numbers.

Psychedelics News March 2020

Although we all want to move the field forward, the two first articles highlight problems going forward. Companies are still making waves and MindMed goes public. Psymposia stays critical as ever about the capitalist moves being made. And a study got people to ‘trip’ in a cleverly designed setting.

Psychedelics Research Recap February 2020

Psychedelics may not be ready to be accepted by the FDA (more research needs to be done). The use of psilocybin has positive effects one month later, but repeated and high-dose usage is correlated with more negative outcomes. And microdosing may have a positive effect on mental disorders as reported by users.